Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:52:45.408Z.
Calculation as of: 2026-10-06T18:52:45.408Z.
Quote observation: 2026-10-06T18:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f0f34e1a3c3db59aa089d09e3018975893bb9567e33ddb8ff6924431e0b2b95
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$3.49B
Price/OCF Ratio
N/A
TTM Avg
11.75
3Y Avg
11.73
5Y Avg
11.73
Market Cap
$3.38B
Price/OCF Ratio
17.42
TTM Avg
27.05
3Y Avg
38.50
5Y Avg
38.50
Market Cap
$3.51B
Price/OCF Ratio
N/A
TTM Avg
627.91
3Y Avg
627.91
5Y Avg
627.91
Market Cap
$3.53B
Price/OCF Ratio
N/A
TTM Avg
14.77
3Y Avg
14.77
5Y Avg
14.77
Market Cap
$3.55B
Price/OCF Ratio
41.28
TTM Avg
62.20
3Y Avg
178.64
5Y Avg
178.64
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulse Biosciences, Inc. (PLSE) | $3.44B | N/A | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | N/A | 11.75 | 11.73 | 11.73 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 17.42 | 27.05 | 38.50 | 38.50 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | N/A | 627.91 | 627.91 | 627.91 |
| CareDx, Inc (CDNA)vs › | $3.36B | 35.90 | 25.34 | 102.30 | 213.86 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.53B | N/A | 14.77 | 14.77 | 14.77 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | 41.28 | 62.20 | 178.64 | 178.64 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A | N/A | N/A | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 19.93 | 25.33 | 35.68 | 1376.29 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
